LONDON, March 31, 2025 /PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 Million in its first external funding round.

Alphabet’s secretive drug discovery arm, Isomorphic Labs, is getting ready to start testing its AI-designed drugs in humans, Colin Murdoch, Isomorphic Labs president and Google DeepMind’s chief ...

Isomorphic Labs Inc., a healthcare startup that spun out of Alphabet Inc. in 2021, today announced that it has closed a $600 million funding round. OpenAI backer Thrive Capital led the investment.

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, according to the Financial Times. The AI-first drug design ...

Isomorphic will use the windfall to fund development of its next-generation artificial intelligence drug design model, the company announced in a March 31 release. The AI biotech is also looking ...

Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is ...

Isomorphic Labs founder and CEO, Sir Demis Hassabis, PhD “This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs ...